Neopharm Ltd Stock Cash Per Share
| 092730 Stock | KRW 11,950 10.00 0.08% |
NeoPharm LTD fundamentals help investors to digest information that contributes to NeoPharm's financial success or failures. It also enables traders to predict the movement of NeoPharm Stock. The fundamental analysis module provides a way to measure NeoPharm's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to NeoPharm stock.
NeoPharm |
NeoPharm LTD Company Cash Per Share Analysis
NeoPharm's Cash per Share is a ratio of current cash on hands or in the banks of the company to a total number of shares outstanding. It is used to determine a firm's liquidity and is a good indicator of the overall financial health of a company. Value investors often compare this ratio to the current stock quote, and if it exceeds the stock price they would invest in it.
Companies with high Cash per Share ratio will be considered as an attractive investment by most investors. In most industries if you can single out an equity instrument trading below its cash per share value, you have a bargain and should consider buying it. Finding the stocks traded below their cash value, therefore, can be a good starting point for investors using strategies based on fundamentals.
| Competition |
In accordance with the recently published financial statements, NeoPharm LTD has a Cash Per Share of 0.0 times. This indicator is about the same for the Personal Products average (which is currently at 0.0) sector and about the same as Consumer Staples (which currently averages 0.0) industry. This indicator is about the same for all Republic of Korea stocks average (which is currently at 0.0).
Did you try this?
Run Portfolio Dashboard Now
Portfolio DashboardPortfolio dashboard that provides centralized access to all your investments |
| All Next | Launch Module |
NeoPharm Fundamentals
| Return On Equity | 13.82 | |||
| Return On Asset | 0.11 | |||
| Profit Margin | 0.21 % | |||
| Operating Margin | 0.26 % | |||
| Current Valuation | 153.58 B | |||
| Shares Outstanding | 7.99 M | |||
| Shares Owned By Insiders | 38.94 % | |||
| Shares Owned By Institutions | 17.81 % | |||
| Price To Earning | 42.54 X | |||
| Price To Sales | 1.56 X | |||
| Revenue | 87.93 B | |||
| Gross Profit | 58.64 B | |||
| EBITDA | 24.3 B | |||
| Net Income | 17.71 B | |||
| Cash And Equivalents | 7.05 B | |||
| Total Debt | 101.79 M | |||
| Debt To Equity | 0.60 % | |||
| Current Ratio | 4.20 X | |||
| Book Value Per Share | 4,777 X | |||
| Cash Flow From Operations | 21.68 B | |||
| Earnings Per Share | 576.00 X | |||
| Target Price | 36000.0 | |||
| Number Of Employees | 106 | |||
| Beta | 1.11 | |||
| Market Capitalization | 156.02 B | |||
| Total Asset | 143.41 B | |||
| Retained Earnings | 19.71 B | |||
| Working Capital | 16.77 B | |||
| Current Asset | 22.83 B | |||
| Current Liabilities | 6.06 B | |||
| Annual Yield | 0.03 % | |||
| Net Asset | 143.41 B |
About NeoPharm Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze NeoPharm LTD's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of NeoPharm using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of NeoPharm LTD based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Pair Trading with NeoPharm
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if NeoPharm position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in NeoPharm will appreciate offsetting losses from the drop in the long position's value.Moving against NeoPharm Stock
The ability to find closely correlated positions to NeoPharm could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace NeoPharm when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back NeoPharm - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling NeoPharm LTD to buy it.
The correlation of NeoPharm is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as NeoPharm moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if NeoPharm LTD moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for NeoPharm can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Other Information on Investing in NeoPharm Stock
NeoPharm financial ratios help investors to determine whether NeoPharm Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in NeoPharm with respect to the benefits of owning NeoPharm security.